BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients

QR Code

BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients

None

Saved in:

Bibliographic Details
Main Authors:	Vallacchi, Viviana, Rivoltini, Licia, Rodolfo, Monica
Format:	Electronic Book Chapter
Language:	English
Published:	IntechOpen 2011
Subjects:	Health Sciences
Online Access:	https://www.intechopen.com/chapters/19097
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable <i>BRAF</i> V600-mutated metastatic melanoma in Russia
by: N. A. Avxentyev, et al.
Published: (2023-11-01)

Systemic therapy of skin metastatic melanoma with BRAF gene mutation
by: Yu. S. Shakh-Paronyants, et al.
Published: (2023-03-01)

Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study
by: Clara Mayo de las Casas, et al.
Published: (2025-01-01)

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
by: Bethy S Hernowo, et al.
Published: (2016-05-01)

Use of BRAF V600E as a Molecular Marker in Aggressive Colorectal Cancer
by: Bethy S Hernowo, et al.
Published: (2016-05-01)

Transsulfuration Reprogramming: A Metabolic Driver of BRAF‐V600E Resistance in Melanoma
by: Juntong Chen, et al.
Published: (2025-06-01)

Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers
by: Pawel Sadlecki, et al.
Published: (2017-05-01)

BRAF V600E Mutation Detection Using High Resolution Probe Melting Analysis
by: Hardingham, Jennifer E., et al.
Published: (2012)

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
by: Ada Ndoja, et al.
Published: (2025-06-01)

Sialadenoma papilliferum-like intraductal papillary tumor of the mandible with BRAF V600E mutation: A rare case report
by: Sak Lee, et al.
Published: (2025-07-01)

Association between braf gene mutation status and clinical-morphological features of cutaneous melanoma
by: O. I. Kit, et al.
Published: (2016-06-01)

Clinical impact of first-line therapeutic strategies in BRAF V600E-mutant metastatic colorectal cancer: real-world evidence and prognostic insight
by: Chia-Chang Yeh, et al.
Published: (2025-07-01)

Investigating therapeutic efficacy of dacarbazine and temozolomide, alone and in combination with BRAF(V600E) siRNA in A375 human melanoma cell line
by: Fatemeh Tabandeh, et al.
Published: (2025-06-01)

Eosinophilic Cells as a Distinct Morphological Feature in <i>BRAF<sup>V600E</sup></i>-Mutated Ovarian Serous Borderline Tumors
by: Alina Badlaeva, et al.
Published: (2025-06-01)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022-07-01)

The combination of mutations in BRAF and NRAS genes within a one tumor in patients with cutaneous melanoma
by: M. B. Aksenenko, et al.
Published: (2019-10-01)

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis.
by: Gholamreza Safaee Ardekani, et al.
Published: (2012-01-01)

Axillary cutaneous metastasis of colon cancer with microsatellite instability-high and BRAF V600E mutation treated with curative-intent surgery: a case report
by: Daisuke Yamai, et al.
Published: (2023-11-01)

Combined target therapy (dabrafenib and trametinib) in the treatment of metastatic <i>BRAF</i><sup> V600E </sup>-positive anaplastic thyroid cancer: clinical cases
by: S. S. Lebedev, et al.
Published: (2025-05-01)

DETECTION OF SOMATIC MUTATIONS IN THE BRAF GENE BY PYROSEQUENCING
by: O. P. Dribnokhodova, et al.
Published: (2021-10-01)

TREATMENT OF <em>BRAF</em><sup>V600E</sup> POSITIVE ANAPLASTIC THYROID CARCINOMA: CASE REPORT
by: P. A. Nikiforovich, et al.
Published: (2020-10-01)

Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells
by: Girolamo Spagnoletti, et al.
Published: (2018-04-01)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis.
by: David S Nelson, et al.
Published: (2019-01-01)

Identifying a wide range of mutations in the <i>BRAF</i> gene for prescribing targeted drugs for melanoma treatment
by: A. N. Toropovskiy, et al.
Published: (2023-03-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)

Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case
by: V. E. Askarov, et al.
Published: (2025-07-01)

KIT, NRAS and BRAF mutations in head and neck (upper aerodigestive tract) mucosal melanoma (a study of 21 cases)
by: A. V. Ignatova, et al.
Published: (2017-04-01)

Mutaciones de KIT, NRAS y BRAF en melanoma
by: Luz de María Díaz-Granados, et al.
Published: (2019-08-01)

ANALYSIS OF MUTATIONS IN KRAS AND BRAF GENES IN COLORECTAL CANCER IN RUSSIAN PATIENTS
by: E. E. Pisareva, et al.
Published: (2016-07-01)

Vemurafenib Induces Senescent Phenotype with Increased Adhesion in BRAF Mutant A375 but not in Wild Type BRAF SK-MEL-2 Melanoma Cells
by: Aleksandra Rashidovna Esimbekova, et al.
Published: (2025-04-01)

Circulating Melanoma Cells
by: Ziman, Mel
Published: (2011)

Phenotypic plasticity of metastatic melanoma
by: I. N. Mikhaylova, et al.
Published: (2019-02-01)

THE ROLE OF BRAF MUTATION STATUS IN SURGICAL TREATMENT OF WELL-DIFFERENTIATED THYROID CANCER
by: A. P. Polyakov, et al.
Published: (2017-04-01)

Promising Experimental Therapies for Metastatic Melanoma
by: Lam, Bao, et al.
Published: (2011)

The relationship of clinical and morphological parameters with the BRAF status of the tumor in patients with stage I skin melanoma
by: K. S. Titov, et al.
Published: (2024-09-01)

Rescue of cell cycle progression in BRAF inhibitor–resistant human melanoma by a chromatin modifier
by: Antoni X Torres-Collado, et al.
Published: (2017-09-01)

Site‐Specific Mutations on KRAS, NRAS, and BRAF Corelate With the Frequency of ctDNA in Colorectal Cancer
by: Fumihiro Yoshimura, et al.
Published: (2025-07-01)

Resistance to MAPK Pathway Inhibition in <i>BRAF</i>-V600E Mutant Colorectal Cancer Can Be Overcome with Insulin Receptor/Insulin-like Growth Factor-1 Receptor Inhibitors
by: Layla El Bouazzaoui, et al.
Published: (2025-06-01)

Immune-Therapy in Cutaneous Melanoma – Efficacy Immune Markers
by: Neagu, Monica, et al.
Published: (2012)

BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis.
by: Dong Chen, et al.
Published: (2014-01-01)